BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 29917073)

  • 21. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
    Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
    World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer.
    Tamandl D; Fueger B; Haug A; Schmid R; Stift J; Schoppmann SF; Ilhan-Mutlu A; Ba-Ssalamah A
    Clin Nucl Med; 2019 Jan; 44(1):e13-e21. PubMed ID: 30418211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
    Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
    Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of
    Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer.
    Goel R; Subramaniam RM; Wachsmann JW
    PET Clin; 2017 Oct; 12(4):373-391. PubMed ID: 28867110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
    Valkema MJ; de Lussanet de la Sablonière QG; Valkema R; Thomeer MGJ; Dwarkasing RS; Harteveld AA; Doukas M; Mostert B; van der Zijden CJ; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Verburg FA; van Lanschot JJB
    Nucl Med Commun; 2024 Feb; 45(2):128-138. PubMed ID: 37982560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST.
    Albano D; Mattia B; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2020 Mar; 45(3):644-651. PubMed ID: 31646354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis.
    Burglin SA; Hess S; Høilund-Carlsen PF; Gerke O
    Medicine (Baltimore); 2017 Apr; 96(16):e6713. PubMed ID: 28422888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging investigations for oesophageal cancer: a meta-analysis.
    van Vliet EP; Heijenbrok-Kal MH; Hunink MG; Kuipers EJ; Siersema PD
    Br J Cancer; 2008 Feb; 98(3):547-57. PubMed ID: 18212745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
    Gabrielson S; Sanchez-Crespo A; Klevebro F; Axelsson R; Albert Tsai J; Johansson O; Nilsson M
    Acta Radiol; 2019 May; 60(5):578-585. PubMed ID: 30111193
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Lamarca A; Barriuso J; Chander A; McNamara MG; Hubner RA; ÓReilly D; Manoharan P; Valle JW
    J Hepatol; 2019 Jul; 71(1):115-129. PubMed ID: 30797051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
    Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
    Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of
    Liu F; Zhang Q; Zhou D; Dong J
    BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.